Choosing Wisely: how the UK intends to reduce harmful medical overuseBMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j370 (Published 26 January 2017) Cite this as: BMJ 2017;356:j370
- Jacqui Wise, freelance journalist, London, UK
The Choosing Wisely campaign in the UK, launched by the Academy of Medical Royal Colleges in October last year, lists 40 tests and treatments that are unlikely to benefit patients.1 2 For example, the campaign advises that uncomplicated back pain does not usually require imaging; screening for prostate specific antigen does not lead to longer life; and chemotherapy for patients with terminal cancer may cause harm and should be minimised.
The campaign aims to encourage doctors and patients to have a conversation about the risks and benefits of interventions. Joan Reid, policy manager for the Choosing Wisely campaign, told the BMJ: “Medicine has developed to such an extent that we now have an armoury of tests, treatments, and procedures for any given disease whereas a couple of decades ago we didn’t have that same choice. So the doctor needs to have a detailed discussion with the patient about their experience, their lifestyle, their attitude to risk, and their social circumstances.”
Choosing Wisely was developed in the United States in 2012 by the American Board of Internal Medicine Foundation (www.choosingwisely.org). The US list has 450 tests and treatments that are unlikely to be of benefit, supported by many resources, including education modules for doctors and materials for patients. Canada, Australia, Germany, Italy, Japan, Netherlands, and Switzerland have similar campaigns.
For the UK list, the academy asked all of the 24 medical royal colleges and faculties to propose “five tests, treatments, or procedures which have questionable benefits and should prompt a careful discussion with patients rather than being carried out without question.” Each college or faculty appointed a Choosing Wisely lead, and it …